Clinical trial for PLB1004
2022-09-26
PLB1004 is a small-molecule inhibitor for epidermal growth factor receptor (EGFR) autonomously researched in China with international intellectual property rights. It is used to treat late-stage non-small cell lung cancer caused by EGFR mutation.
View Details >
2022-09-26
Vebreltinib clinical study
Vebreltinib is a highly selective MET kinase inhibitor. Abnormal activation of the MET pathway can lead to tumor proliferation, invasion and metastasis. Beratinib can effectively inhibit the activation of the MET pathway and benefit patients with abnormal MET.
View Details >
Company Profile
©2022 Beijing Avistone Pharmaceuticals Biotechnology Co., Ltd.
京ICP备2020040683号-2